Implementing pre-exposure prophylaxis for HIV prevention in women: the role of the obstetrician-gynecologist

Published:December 29, 2021DOI:
      Pre-exposure prophylaxis is a powerful HIV prevention tool that can reduce the risk of acquiring HIV by >90% from unprotected sex and >70% from injection drug use. The peripartum period is a time of heightened HIV risk, which underscores the need for HIV prevention counseling and the provision of biomedical interventions in all stages of a woman’s reproductive life. It is important that women receive nonjudgmental care, have access to discussions of HIV risk, and are provided with pre-exposure prophylaxis counseling from their women’s health practitioners. Obstetrician-gynecologists and other women’s health providers are uniquely positioned to identify women who would benefit from pre-exposure prophylaxis and provide it in trusted clinical settings.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Centers for Disease Control and Prevention
        HIV surveillance report, 2018 (updated).
        (Available at:) (Accessed December 8, 2019)
        • King E.M.
        • Albert A.Y.
        • Murray M.C.M.
        HIV and amenorrhea: a meta-analysis.
        AIDS. 2019; 33: 483-491
        • Jamieson D.J.
        • Duerr A.
        • Burk R.
        • et al.
        Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection.
        Am J Obstet Gynecol. 2002; 186: 21-27
        • Cejtin H.E.
        • Kalinowski A.
        • Bacchetti P.
        • et al.
        Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction.
        Obstet Gynecol. 2006; 108: 1423-1431
        • LaGuardia K.D.
        • White M.H.
        • Saigo P.E.
        • Hoda S.
        • McGuinness K.
        • Ledger W.J.
        Genital ulcer disease in women infected with human immunodeficiency virus.
        Am J Obstet Gynecol. 1995; 172: 553-562
        • Patel P.
        • Borkowf C.B.
        • Brooks J.T.
        • Lasry A.
        • Lansky A.
        • Mermin J.
        Estimating per-act HIV transmission risk: a systematic review.
        AIDS. 2014; 28: 1509-1519
      1. Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV.
        BMJ. 1992; 304: 809-813
        • Jenness S.M.
        • Neaigus A.
        • Murrill C.S.
        • Wendel T.
        • Forgione L.
        • Hagan H.
        Estimated HIV incidence among high-risk heterosexuals in New York City, 2007.
        J Acquir Immune Defic Syndr. 2011; 56: 193-197
        • Baggaley R.F.
        • White R.G.
        • Boily M.C.
        HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention.
        Int J Epidemiol. 2010; 39: 1048-1063
        • Adimora A.A.
        • Auerbach J.D.
        Structural interventions for HIV prevention in the United States.
        J Acquir Immune Defic Syndr. 2010; 55: S132-S135
        • Sipe T.A.
        • Barham T.L.
        • Johnson W.D.
        • Joseph H.A.
        • Tungol-Ashmon M.L.
        • O’Leary A.
        Structural interventions in HIV prevention: a taxonomy and descriptive systematic review.
        AIDS Behav. 2017; 21: 3366-3430
        • Krishnaratne S.
        • Hensen B.
        • Cordes J.
        • Enstone J.
        • Hargreaves J.R.
        Interventions to strengthen the HIV prevention cascade: a systematic review of reviews.
        Lancet HIV. 2016; 3: e307-e317
        • Cohen M.S.
        • Chen Y.Q.
        • McCauley M.
        • et al.
        Antiretroviral therapy for the prevention of HIV-1 transmission.
        N Engl J Med. 2016; 375: 830-839
        • LeMessurier J.
        • Traversy G.
        • Varsaneux O.
        • et al.
        Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review.
        CMAJ. 2018; 190: E1350-E1360
        • Drew W.L.
        • Blair M.
        • Miner R.C.
        • Conant M.
        Evaluation of the virus permeability of a new condom for women.
        Sex Transm Dis. 1990; 17: 110-112
        • Weller S.
        • Davis K.
        Condom effectiveness in reducing heterosexual HIV transmission.
        Cochrane Database Syst Rev. 2002; : CD003255
        • Hunt A.
        FDA in brief: FDA continues to encourage ongoing education about the benefits and risks associated with PrEP, including additional steps to help reduce the risk of getting HIV. US Food and Drug Administration.
        (Available at:) (Accessed December 8, 2019)
        • Trezza C.R.
        • Kashuba A.D.
        Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.
        Clin Pharmacokinet. 2014; 53: 611-624
        • Mayer K.H.
        • Molina J.M.
        • Thompson M.A.
        • et al.
        Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCover): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
        Lancet. 2020; 396: 239-254
        • Centers for Disease Control and Prevention
        US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline.
        Centers for Disease Control and Prevention, 2018 (Available at:)
        • Baeten J.M.
        • Donnell D.
        • Ndase P.
        • et al.
        Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
        N Engl J Med. 2012; 367: 399-410
        • Grant R.M.
        • Lama J.R.
        • Anderson P.L.
        • et al.
        Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
        N Engl J Med. 2010; 363: 2587-2599
        • Thigpen M.C.
        • Kebaabetswe P.M.
        • Paxton L.A.
        • et al.
        Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
        N Engl J Med. 2012; 367: 423-434
        • Marrazzo J.M.
        • Ramjee G.
        • Richardson B.A.
        • et al.
        Tenofovir-based preexposure prophylaxis for HIV infection among African women.
        N Engl J Med. 2015; 372: 509-518
        • Van Damme L.
        • Corneli A.
        • Ahmed K.
        • et al.
        Preexposure prophylaxis for HIV infection among African women.
        N Engl J Med. 2012; 367: 411-422
        • Hanscom B.
        • Janes H.E.
        • Guarino P.D.
        • et al.
        Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence.
        J Acquir Immune Defic Syndr. 2016; 73: 606-608
        • Cottrell M.L.
        • Yang K.H.
        • Prince H.M.
        • et al.
        A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine.
        J Infect Dis. 2016; 214: 55-64
        • Bradley E.
        • Forsberg K.
        • Betts J.E.
        • et al.
        Factors affecting pre-exposure prophylaxis implementation for women in the United States: a systematic review.
        J Womens Health (Larchmt). 2019; 28: 1272-1285
        • Choopanya K.
        • Martin M.
        • Suntharasamai P.
        • et al.
        Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
        Lancet. 2013; 381: 2083-2090
        • Karim S.S.
        HIV pre-exposure prophylaxis in injecting drug users.
        Lancet. 2013; 381: 2060-2062
        • Thomson K.A.
        • Hughes J.
        • Baeten J.M.
        • et al.
        Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners.
        J Infect Dis. 2018; 218: 16-25
        • Garcia P.M.
        • Kalish L.A.
        • Pitt J.
        • et al.
        Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.
        N Engl J Med. 1999; 341: 394-402
        • Mofenson L.M.
        • Baggaley R.C.
        • Mameletzis I.
        Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
        AIDS. 2017; 31: 213-232
        • Antiretroviral Pregnancy Registry. Antiretroviral Pregnancy Registry Steering Committee
        Antiretroviral Pregnancy Registry interim report for 1 January 1989 through 31 July 2021.
        (Available at:) (Accessed July 30, 2021)
        • Hu X.
        • Wang L.
        • Xu F.
        Guides concerning tenofovir exposure via breastfeeding: a comparison of drug dosages by developmental stage.
        Int J Infect Dis. 2019; 87: 8-12
        • Mugwanya K.K.
        • Hendrix C.W.
        • Mugo N.R.
        • et al.
        Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption.
        PLoS Med. 2016; 13e1002132
        • World Health Organization
        WHO technical brief: preventing HIV during pregnancy and breastfeeding in the context of pre-exposure prophylaxis (PrEP).
        (Available at:) (Accessed December 8, 2019)
        • Smith D.K.
        • Van Handel M.
        • Grey J.
        Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015.
        Ann Epidemiol. 2018; 28: 850-857.e9
        • Huang Y.A.
        • Zhu W.
        • Smith D.K.
        • Harris N.
        • Hoover K.W.
        HIV preexposure prophylaxis, by race and ethnicity - United States, 2014-2016.
        MMWR Morb Mortal Wkly Rep. 2018; 67: 1147-1150
        • AIDSVu
        Tools & Resources. Deeper Look.
        (Available at:) (Accessed December 8, 2019)
        • Calabrese S.K.
        • Krakower D.S.
        • Mayer K.H.
        Integrating HIV preexposure prophylaxis (PrEP) into routine preventive health care to avoid exacerbating disparities.
        Am J Public Health. 2017; 107: 1883-1889
        • Pellowski J.A.
        • Kalichman S.C.
        • Matthews K.A.
        • Adler N.
        A pandemic of the poor: social disadvantage and the U.S. HIV epidemic.
        Am Psychol. 2013; 68: 197-209
        • Ojikutu B.O.
        • Mayer K.H.
        Hidden in plain sight: identifying women living in the United States who could benefit from HIV preexposure prophylaxis.
        J Infect Dis. 2020; 222: 1428-1431
        • Pinto R.M.
        • Berringer K.R.
        • Melendez R.
        • Mmeje O.
        Improving PrEP implementation through multilevel interventions: a synthesis of the literature.
        AIDS Behav. 2018; 22: 3681-3691
        • Patel A.S.
        • Goparaju L.
        • Sales J.M.
        • et al.
        Brief report: PrEP eligibility among at-risk women in the Southern United States: associated factors, awareness, and acceptability.
        J Acquir Immune Defic Syndr. 2019; 80: 527-532
        • Garfinkel D.B.
        • Alexander K.A.
        • McDonald-Mosley R.
        • Willie T.C.
        • Decker M.R.
        Predictors of HIV-related risk perception and PrEP acceptability among young adult female family planning patients.
        AIDS Care. 2017; 29: 751-758
        • Khawcharoenporn T.
        • Kendrick S.
        • Smith K.
        HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic.
        AIDS Patient Care STDs. 2012; 26: 222-233
        • Goparaju L.
        • Experton L.S.
        • Praschan N.C.
        • Warren-Jeanpiere L.
        • Young M.A.
        • Kassaye S.
        Women want pre-exposure prophylaxis but are advised against it by their HIV-positive counterparts.
        J AIDS Clin Res. 2015; 6: 1-10
        • Roth A.M.
        • Tran N.K.
        • Felsher M.
        • et al.
        Integrating HIV preexposure prophylaxis with community-based syringe services for women who inject drugs: results from the Project SHE Demonstration Study.
        J Acquir Immune Defic Syndr. 2021; 86: e61-e70
        • Flash C.A.
        • Adegboyega O.O.
        • Yu X.
        • et al.
        Correlates of linkage to HIV preexposure prophylaxis among HIV-testing clients.
        J Acquir Immune Defic Syndr. 2018; 77: 365-372
        • Mayer K.H.
        • Agwu A.
        • Malebranche D.
        Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review.
        Adv Ther. 2020; 37: 1778-1811
        • Seidman D.
        • Carlson K.
        • Weber S.
        • Witt J.
        • Kelly P.J.
        United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey.
        Contraception. 2016; 93: 463-469
        • Kole M.
        • Scott M.
        • Brar I.
        • Sangha R.
        Do you PrEP? Knowledge and practice among obstetrician and gynecologists in an inner city hospital [16Q].
        Obstet Gynecol. 2019; 133: 185S
        • Centers for Disease Control and Prevention
        US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Centers for Disease Control and Prevention.
        (Available at:) (Accessed December 17, 2021)
        • Calabrese S.K.
        • Krakower D.S.
        • Willie T.C.
        • Kershaw T.S.
        • Mayer K.H.
        US guideline criteria for human immunodeficiency virus preexposure prophylaxis: clinical considerations and caveats.
        Clin Infect Dis. 2019; 69: 884-889
        • Calabrese S.K.
        • Willie T.C.
        • Galvao R.W.
        • et al.
        Current US guidelines for prescribing HIV pre-exposure prophylaxis (PrEP) disqualify many women who are at risk and motivated to use PrEP.
        J Acquir Immune Defic Syndr. 2019; 81: 395-405
      2. Truvada (emtricitabine and tenofovir disoproxil fumarate) tablets, for oral use [Package insert].∼/media/files/pdfs/medicines/hiv/truvada/truvada_pi.pdf.

        • Thomson K.A.
        • Baeten J.M.
        • Mugo N.R.
        • Bekker L.G.
        • Celum C.L.
        • Heffron R.
        Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
        Curr Opin HIV AIDS. 2016; 11: 18-26
        • Seidman D.
        • Weber S.
        Integrating preexposure prophylaxis for human immunodeficiency virus prevention into Women’s Health Care in the United States.
        Obstet Gynecol. 2016; 128: 37-43
        • Haberer J.E.
        Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
        Curr Opin HIV AIDS. 2016; 11: 10-17
        • Touger R.
        • Wood B.R.
        A review of telehealth innovations for HIV pre-exposure prophylaxis (PrEP).
        Curr HIV/AIDS Rep. 2019; 16: 113-119
        • Schürmann D.
        • Rudd D.J.
        • Zhang S.
        • et al.
        Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
        Lancet HIV. 2020; 7: e164-e172
        Pharmacokinetic study of cabotegravir long-acting in healthy adult volunteers.
        (Available at:) (Accessed January 28, 2021)
        • HPTN
        A phase 3 double blind safety and efficacy study of long-acting injectable cabotegravir compared to daily oral TDF/FTC for pre-exposure prophylaxis in HIV-uninfected women. HIV prevention trials network.
        (Available at:) (Accessed June 30, 2021)
        • Nel A.
        • van Niekerk N.
        • Kapiga S.
        • et al.
        Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.
        N Engl J Med. 2016; 375: 2133-2143
        • Baeten J.M.
        • Palanee-Phillips T.
        • Brown E.R.
        • et al.
        Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
        N Engl J Med. 2016; 375: 2121-2132
        • World Health Organization
        WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection.
        (Available at:) (Accessed January 28, 2021)